Fuan Pharmaceutical (Group) Co., Ltd.

SZSE:300194 Stock Report

Market Cap: CN¥5.7b

Fuan Pharmaceutical (Group) Balance Sheet Health

Financial Health criteria checks 5/6

Fuan Pharmaceutical (Group) has a total shareholder equity of CN¥4.4B and total debt of CN¥709.9M, which brings its debt-to-equity ratio to 16.1%. Its total assets and total liabilities are CN¥6.0B and CN¥1.6B respectively. Fuan Pharmaceutical (Group)'s EBIT is CN¥258.4M making its interest coverage ratio -3.2. It has cash and short-term investments of CN¥969.1M.

Key information

16.1%

Debt to equity ratio

CN¥709.91m

Debt

Interest coverage ratio-3.2x
CashCN¥969.06m
EquityCN¥4.40b
Total liabilitiesCN¥1.64b
Total assetsCN¥6.04b

Recent financial health updates

Recent updates

Fuan Pharmaceutical (Group) Co., Ltd. (SZSE:300194) Shares Fly 36% But Investors Aren't Buying For Growth

Oct 08
Fuan Pharmaceutical (Group) Co., Ltd. (SZSE:300194) Shares Fly 36% But Investors Aren't Buying For Growth

There's No Escaping Fuan Pharmaceutical (Group) Co., Ltd.'s (SZSE:300194) Muted Earnings

Aug 23
There's No Escaping Fuan Pharmaceutical (Group) Co., Ltd.'s (SZSE:300194) Muted Earnings

Does Fuan Pharmaceutical (Group) (SZSE:300194) Have A Healthy Balance Sheet?

Jun 07
Does Fuan Pharmaceutical (Group) (SZSE:300194) Have A Healthy Balance Sheet?

Fuan Pharmaceutical (Group)'s (SZSE:300194) Shareholders May Want To Dig Deeper Than Statutory Profit

May 02
Fuan Pharmaceutical (Group)'s (SZSE:300194) Shareholders May Want To Dig Deeper Than Statutory Profit

Insufficient Growth At Fuan Pharmaceutical (Group) Co., Ltd. (SZSE:300194) Hampers Share Price

Apr 03
Insufficient Growth At Fuan Pharmaceutical (Group) Co., Ltd. (SZSE:300194) Hampers Share Price

Financial Position Analysis

Short Term Liabilities: 300194's short term assets (CN¥2.2B) exceed its short term liabilities (CN¥1.3B).

Long Term Liabilities: 300194's short term assets (CN¥2.2B) exceed its long term liabilities (CN¥326.9M).


Debt to Equity History and Analysis

Debt Level: 300194 has more cash than its total debt.

Reducing Debt: 300194's debt to equity ratio has increased from 1.3% to 16.1% over the past 5 years.

Debt Coverage: 300194's debt is well covered by operating cash flow (65.1%).

Interest Coverage: 300194 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 12:57
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Fuan Pharmaceutical (Group) Co., Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jie YaoEverbright Securities Co. Ltd.
Guang WangGuoyuan Securities Co., Ltd.
Yi YaoHuatai Research